Strides Pharma Science gets USFDA approval for Celecoxib capsules
Bengaluru-based Strides Pharma Science Limited (Strides) on Wednesday said that its step-down wholly-owned subsidiary, Strides Pharma Global Pte. Limited, Singapore, has received approval for Celecoxib Capsules, 100 mg, 200 mg, and 400 mg, from the United States Food & Drug Administration (USFDA).
The product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Celebrex Capsules, 100 mg, 200 mg, and 400 mg, of Upjohn US 2 LLC, and would be manufactured at the company's facility in Puducherry, according to a company statement.
The approval of Celecoxib Capsules would strengthen Strides' portfolio in the anti-inflammatory therapeutic segment, it further said. Celecoxib is a selective COX-2 inhibitor used for the management of pain and inflammation associated with various conditions including osteoarthritis, rheumatoid arthritis, acute pain, and dysmenorrhea. Celecoxib Capsules, 100 mg, 200 mg, and 400 mg have a combined market size of $116 Mn as per IMS.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
2 hours ago
- Time of India
Adani plans projects worth 17,500cr to expand CSMIA's capacity by '29
New Delhi: The Adani group has identified a string of projects — well over 310 that will require a capex of about Rs 17,500 crore by March 2029 — to augment the annual passenger handling capacity of Mumbai's Chhatrapati Shivaji Maharaj International Airport (CSMIA) to 6.5 crore passengers annually (CPA). The projects include building a bigger Terminal 1 in place of the existing terminal, expanding Terminal 2's capacity from 4 CPA to 4.5 CPA and increasing the hourly flight handling capacity to over 52. By 2029-30, the combined capacity of CSMIA and the upcoming Navi Mumbai International Airport (NMIA) is expected to touch 11.5 CPA, to "cater to the growing demands of Mumbai region and Mumbai Metropolitan Region", shows an order issued by the Airports Economic Regulatory Authority (AERA) recently. Mumbai International Airport Ltd (MIAL) "has proposed extending existing taxiway M to link it with the physical beginning of runway 27, including the construction of a bridge over Mithi river. The proposed Taxiway M extension will create an additional holding area for aircraft.… It will be designed for Code F aircraft (that include Boeing 747-8 and Airbus A380)," the order states. The hub had handled its highest ever passenger number of almost 5.5 crore in CY 2024. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Esta nueva alarma con cámara es casi regalada en Campo Lope Seco (ver precio) Verisure Since last Feb, CSMIA which has a set of cross runways — making it essentially a single runway airport — is handling upto 44 flights (down from earlier 46) during "high intensity runway operations" (HIRO) periods from 8-11am and 5-8pm. And upto 42 aircraft movement per hour (down from earlier 44) during non-HIRO period. This is now set to get a big bost in the next 3-4 years. "Some of such projects identified for implementation for enabling the airport to cater to 6.5 CPA capacity are: Reconstruction of TI to enhance the capacity from 1.5 CPA to 2 CPA. Terminal 2 northwest pier (check-in facilities, construction of bus boarding Gates (V3) T2 expansion to enhance the capacity to 4.5 CPA. Additional aircraft parking stands in the southern side of runway 09-27," states the AERA order. The other steps include construction of parking stand, constructing an airside tunnel, and an eastern taxiway parallel to runway 14-32. AERA had asked MIAL to engage UK-based National Air Traffic Services (NATS) "to provide an independent high-level review of the infrastructure and forecast demand contained in CSMIA master plan. NATS has done a study and has confirmed the peak hour theoretical capacity of 55 ATMs (aircraft movement) based on its analysis benchmarking with other busy single runway airports like Gatwick but in respect to taxiway infrastructure, it has stated that the 'master plan changes appear to offer significant benefits, but they require more detailed assessment to confirm'. The phasing of the taxiway infrastructure changes should be reviewed to ensure that sufficient capacity is provided as demand grows," the order shows. MIAL has proposed a capex of Rs 17,440 crore in the fourth control period, that is upto March 31, 2029, on the capacity augmentation at CSMIA through the various identified projects related to key areas including airside improvement and passenger terminals. T1 is proposed to be reconstructed at a cost of Rs 3,130 crore by Sept 2028. T2 expansion is projected to cost Rs 142 crore and be over by March 2027. The air traffic control technical block is projected to cost Rs 185 crore and be done by March 2027.
Economic Times
3 hours ago
- Economic Times
KKR-backed IVI to buy ART Fertility Clinics for $450 million
Live Events (You can now subscribe to our (You can now subscribe to our Economic Times WhatsApp channel KKR-backed IVI RMA Global, a US-based leader in infertility treatment, is set to acquire ART Fertility Clinics for $400-450 million, according to people familiar with the matter. The acquisition marks a significant step in IVI RMA's global expansion, adding India to its presence in over 15 countries and more than 190 clinical offices across the US, Europe and Latin parties are in the final stages of documentation for a shareholders' agreement and are hoping to wrap up the transaction by June with private hospitals, the IVF industry in India too is witnessing consolidation as several private equity funds have been aggressive with acquisitions. In 2023, Swedish fund EQT Partners acquired a significant majority stake in Indira IVF, the largest provider of fertility services in India and top five globally in terms of annual IVF cycles, at a $1.1 billion ('9,000 crore) Fertility Clinics began in 2015 as IVI Middle East, an international arm of IVI RMA Global. In 2020, IVI RMA divested the business to Gulf Capital, which rebranded it as ART Fertility Clinics. Since then, the brand has rapidly grown, expanding across West Asia and clinics in Abu Dhabi, Dubai and Al Ain in the UAE as well as 11 centres across India, ART Fertility has established itself as a high-performance network in reproductive medicine. The Indian expansion began in 2021, backed by a $30 million investment from Gulf Fertility operates in big Indian cities including Mumbai, Noida, Ahmedabad, Chennai, Hyderabad, Gurgaon and by Suresh Soni, former co-founder and CEO of Nova IVF Fertility, ART Fertility reports a pregnancy success rate of 70% and has recorded over 5,000 successful pregnancies in under nine to sources, ART Fertility posted revenue of $100-120 million in FY25, with an estimated Ebitda of $35 million."For an Indian healthcare player, a $25-35 million ebitda which is borderline ebitda positive coming from the Middle East would add no value," said a fund manager at a Mumbai-based private equity firm that operates a pan-India IVF chain. "However, IVI being a US player where multiples are low, adding a Middle East business works well."IVI RMA trumped a rival bid by Temasek-backed Cloudnine Hospitals.A KKR spokesperson declined to comment. IVI RMA and ART Fertility did not respond to is the advisor in the is rapidly emerging as one of the world's fastest-growing markets for Assisted Reproductive Technology (ART). However, the sector has scope for expansion at 210 IVF cycles per million people, compared with 1,200 in the US and over 2,000 in affects approximately 15% of Indian couples, a figure expected to rise due to lifestyle factors such as poor diet, stress, late marriages, and to EY, India's IVF market is expected to grow from $793 million in 2020 to $1.45 billion by 2027, at a projected CAGR of 15-20%.India sees around 300,000 IVF cycles annually, with projections suggesting this could grow to 500,000-600,000 cycles by 2030. About 30% of the market is controlled by 10-15 organised players, while the remaining is fragmented among smaller, unorganised clinics. Key players in India's fertility sector include Indira IVF, Nova IVF, Oasis IVF, Bloom Fertility Centre, Bengaluru-based Milann, Morpheus IVF, Ridge IVF, Akanksha IVF and Bourn Hall IVF, the second largest player in India, is owned by Asia Healthcare Holdings (AHH), the single specialty hospitals platform backed by GIC and homegrown PE fund Kedaara Capital owns a minority stake in Oasis Fertility, while Brussels-based fund Verlinvest owns a controlling stake in Ferty9 F, a premier chain of fertility clinics in the AP/Telangana region.
&w=3840&q=100)
Business Standard
4 hours ago
- Business Standard
We're the largest gig worker employer in the country: Rapido cofounders
We're currently in over 35 cities with taxis and aim to be present in every district headquarters, says Rapido Surajeet Das Gupta Bengaluru Listen to This Article Bengaluru-based startup Rapido, which joined the unicorn club last year, has disrupted the mobility business by shifting from a commission to a subscription model for drivers across vehicle categories. It recently added taxis, prompting rivals Ola and Uber to follow suit. Rapido cofounders Pavan Guntupalli and Aravind Sanka, in an interview with Surajeet Das Gupta in Bengaluru, discuss their push to become a mass-market mobility player, ongoing goods and services tax (GST) and regulatory challenges, and the government's electric vehicle (EV) drive. Edited excerpts:
